US 7,250,419 · Application 11/230,493 · Granted Jul 31, 2007
US 7,250,419
Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Estimated expiration
December 2, 2019
Expired 2478 days ago
- Could not fetch continuity data for application 09508195: Resource not found (404)
- Could not fetch continuity data for application PCTSE1999002256: Resource not found (404)
Earliest effective filing
Dec 2, 1999
+ 20 years
Dec 2, 2019
PTA +0d
Dec 2, 2019
TD applied
Dec 2, 2019
Final
Dec 2, 2019
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- September 21, 2005
- Earliest effective filing
- December 2, 1999
- Issue date
- July 31, 2007
- PTA
- 0 days
- Base expiry (before PTA)
- December 2, 2019
December 2, 1999 + 20 years = December 2, 2019
- Continuation of application 10/323,655, filed Dec 20, 2002, issued as US 6,974,868
- Continuation of application 09/508,195, filed Mar 8, 2000, issued as US 6,525,060
- National stage entry of application PCTSE1999002256, filed Dec 2, 1999
- Continuation of application 09/508,195, filed Mar 8, 2000, issued as US 6,525,060
Terminal disclaimers
TD caps expiration to December 2, 2019
US 6,525,060
Could not resolve calculation details
US 7,250,419· Application 11/230,493(from application 11/230,493)Capping patent
Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
- Filing date
- Sep 21, 2005
- Earliest effective filing
- Dec 2, 1999
- Issue date
- Jul 31, 2007
- PTA
- 0 days
- Calculated expiration
- Dec 2, 2019
Continuation of 10/323,655, filed Dec 20, 2002, issued as US 6,974,868
Continuation of 09/508,195, filed Mar 8, 2000, issued as US 6,525,060
National stage entry of PCTSE1999002256, filed Dec 2, 1999
Continuation of 09/508,195, filed Mar 8, 2000, issued as US 6,525,060
Dec 2, 1999 + 20y = Dec 2, 2019
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 11/230,493 · US 7,250,419
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 7,250,419: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US7250419Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.